Nymox Pharmaceutical (NYMXF)
OTHER OTC:NYMXF
Top Page
No summary available
Positive Factors
Focus on Unmet Medical Needs
Targeting unmet medical needs can lead to significant market opportunities if the company successfully develops effective treatments, particularly in aging-related conditions where demand is growing.
Negative Factors
Persistent Financial Losses
Ongoing financial losses and negative equity indicate severe financial instability, which could hinder long-term operations and the ability to fund R&D activities necessary for future growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Focus on Unmet Medical Needs
Targeting unmet medical needs can lead to significant market opportunities if the company successfully develops effective treatments, particularly in aging-related conditions where demand is growing.
Read all positive factors
Nymox Pharmaceutical (NYMXF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.56M
Dividend YieldN/A
Average Volume (3M)21.72K
Price to Earnings (P/E)―
Beta (1Y)-362.88
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding94,540,140
10 Day Avg. Volume24,882
30 Day Avg. Volume21,717
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.38
Price to Sales (P/S)0.00
P/FCF Ratio-3.60
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-9.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nymox Pharmaceutical Business Overview & Revenue Model
Company Description
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (N...
How the Company Makes Money
Nymox Pharmaceutical Corporation makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue by advancing its drug candidates through clinical trials in the hope of achieving re...
Nymox Pharmaceutical Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | ― |
| Gross Profit | -1.00K | -11.00K | -12.00K | -12.00K | ― |
| EBITDA | -4.26M | -8.77M | -6.52M | -12.49M | -11.71M |
| Net Income | -4.49M | -8.84M | -6.58M | -12.54M | -11.74M |
Balance Sheet | |||||
| Total Assets | 654.00K | 627.00K | 1.63M | 2.03M | 4.93M |
| Cash, Cash Equivalents and Short-Term Investments | 74.00K | 70.00K | 1.40M | 830.00K | 3.61M |
| Total Debt | 0.00 | 750.00K | 173.00K | 391.00K | 426.00K |
| Total Liabilities | 7.43M | 3.80M | 2.11M | 1.95M | 2.20M |
| Stockholders Equity | -6.78M | -3.17M | -482.00K | 83.00K | 2.73M |
Cash Flow | |||||
| Free Cash Flow | -2.60M | -4.06M | -5.21M | -9.83M | -10.05M |
| Operating Cash Flow | -2.60M | -4.06M | -5.21M | -9.82M | -10.04M |
| Investing Cash Flow | 0.00 | -3.00K | 0.00 | -6.00K | -13.00K |
| Financing Cash Flow | 2.60M | 2.73M | 5.78M | 7.04M | 8.42M |
Nymox Pharmaceutical Technical Analysis
Positive
0.08
Price Trends
0.06
Positive
0.06
Positive
0.07
Positive
Market Momentum
<0.01
Positive
54.02
Neutral
46.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NYMXF, the sentiment is Positive. The current price of 0.08 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.06, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 54.02 is Neutral, neither overbought nor oversold. The STOCH value of 46.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NYMXF.
Nymox Pharmaceutical Risk Analysis
Nymox Pharmaceutical disclosed 21 risk factors in its most recent earnings report. Nymox Pharmaceutical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nymox Pharmaceutical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $7.56M | ― | 278.73% | ― | ― | ― | |
50 Neutral | $5.87M | -25.06 | -418.83% | ― | ― | 98.58% | |
48 Neutral | $10.51M | -0.47 | -291.07% | ― | ― | 61.10% | |
44 Neutral | $6.83M | -0.45 | 553.15% | ― | -29.78% | 88.96% | |
41 Neutral | $8.24M | -0.39 | -97.58% | ― | -46.88% | 34.83% | |
39 Underperform | $870.23K | -1.65 | 1211.14% | ― | -59.21% | 68.97% |
* Healthcare Sector Average
NYMXF
Nymox Pharmaceutical
0.08
-0.06
-40.74%
EVGN
Evogene
0.78
-0.31
-28.17%
MBIO
Mustang Bio
0.78
-0.58
-42.59%
LYRA
Lyra Therapeutics
0.49
-5.11
-91.25%
BOLT
Bolt Biotherapeutics
4.29
-2.74
-38.98%
ACXP
Acurx Pharmaceuticals
3.68
-2.88
-43.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―